Results 61 to 70 of about 2,036 (191)
Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.ABSTRACT Background Respiratory syncytial virus (RSV) is a major cause of hospitalizations in young children and older adults in the United States. Monitoring seasonal RSV activity through national surveillance systems and understanding the relationships among RSV surveillance indicators can help ensure timely administration of prevention products and ...
Erin L. Anderson +12 more
wiley +1 more source
Nous estimons que 35 à 45 % des hospitalisations ont été évitées grâce à l’introduction du nirsevimab. Nous estimons que l’introduction du nirsevimab a permis de diminuer de 35 à 45 % les hospitalisations liées à une infection au VRS chez les enfants de ...
T. Braeye +15 more
core +1 more source
Nirsevimab (▼Beyfortus®): un nuevo anticuerpo monoclonal para la profilaxis frente al virus respiratorio sincitial [PDF]
, 2023 Farmacologia; Medicaments; Virus respiratori sincicialFarmacología; Medicamentos; Virus respiratorio sincicialPharmacology; Medicines; Respiratory syncytial virusAquest article tracta del medicament nirsevimab, un nou anticòs monoclonal que actua ...
core
Guideline for the Diagnosis and Management of Heritable IFNAR1 Deficiency in Oceania
Journal of Paediatrics and Child Health, Volume 62, Issue 7, Page 1113-1120, July 2026.ABSTRACT Autosomal recessive interferon alpha and beta receptor subunit 1 (IFNAR1) deficiency is a rare and heritable inborn error of immunity (IEI) predisposing individuals to severe and life‐threatening viral infections. It is more common in people of Western Polynesian ancestry, with estimates of around one in six thousand live births affected, due ...
Cecilia Verryt +17 more
wiley +1 more source
We schatten dat 35 tot 45% van de ziekenhuisopnames is voorkomen door de introductie van nirsevimab. We schatten dat de introductie van nirsevimab heeft geleid tot 35-45% minder ziekenhuisopnames voor een RSV-infectie bij kinderen jonger dan 5 jaar.
T. Braeye +15 more
core +1 more source
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
, 2022 The efficacy and safety of nirsevimab in the treatment of medically attended respiratory syncytial virus (RSV) infections of the lower respiratory tract in otherwise healthy, late preterm and term infants were assessed in the phase 2B1 and phase 3 ...
Simões, Eric A.F. +24 more
core +1 more source
iNew Medicine, Volume 2, Issue 2, June 2026.This illustration integrates key concepts covered in the review, including high‐risk populations, viral structure, host entry factors, the replication cycle, and licensed antibody‐based prevention strategies. ABSTRACT Respiratory syncytial virus (RSV) is a negative‐sense RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae.
Zekai Cheng +3 more
wiley +1 more source
Frontiers in ImmunologyBackgroundRespiratory Syncytial Virus (RSV) is one of the primary pathogen responsible for severe lower respiratory tract infections in preterm infants, placing a significant burden on patients, their families, and society.
Xiaopeng Wang +15 more
doaj +1 more source
Infectious Diseases and TherapyIntroduction Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract disease, and the standard prevention strategy in Japan is limited to high-risk infants.
Shinichi Noto +7 more
doaj +1 more source
Impact of Respiratory Viral Codetections on RSV Disease Burden in Young Children in Primary Care
Influenza and Other Respiratory Viruses, Volume 20, Issue 6, June 2026.ABSTRACT Background Young children with respiratory syncytial virus (RSV) often have viral coinfections. This study assessed the impact of respiratory viral codetections on RSV disease burden in children < 5 years and whether this varies by specific codetected viruses.
Levi Duijst +16 more
wiley +1 more source